Literature DB >> 8087425

c-Myc does not require max for transcriptional activity in PC-12 cells.

V Ribon1, T Leff, A R Saltiel.   

Abstract

The c-Myc proto-oncogene is a basic helix-loop-helix leucine zipper (b/HLH/LZ) protein that participates in cellular growth and differentiation. The expression of c-Myc mRNA is rapidly induced by nerve growth factor (NGF) and epidermal growth factor (EGF) in PC-12 pheochromocytoma cells. In most cell types, c-Myc forms a sequence-specific DNA binding complex with the stable, constitutively expressed Max. This complex can function as a transcriptional regulator. We show here that the expression of Max mRNA or protein was not detected in PC-12 cells. Nevertheless, treatment of PC-12 cells with NGF and serum caused an increase in the expression of the c-Myc protein and the transcription of a reporter gene linked to the Myc/Max DNA binding site. Transcription from the same reporter gene is stimulated by over-expression of c-Myc. These results suggest that c-Myc protein functions as a transcriptional regulator in PC-12 cells despite the lack of Max protein. Therefore, Myc/Max complexes may not be an absolute requirement for Myc-dependent gene expression.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8087425     DOI: 10.1006/mcne.1994.1032

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  9 in total

Review 1.  Transcription-independent functions of MYC: regulation of translation and DNA replication.

Authors:  Michael D Cole; Victoria H Cowling
Journal:  Nat Rev Mol Cell Biol       Date:  2008-08-13       Impact factor: 94.444

Review 2.  Control of vertebrate development by MYC.

Authors:  Peter J Hurlin
Journal:  Cold Spring Harb Perspect Med       Date:  2013-09-01       Impact factor: 6.915

Review 3.  Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity.

Authors:  Patricia L M Dahia
Journal:  Nat Rev Cancer       Date:  2014-01-20       Impact factor: 60.716

Review 4.  Signaling pathways in pheochromocytomas and paragangliomas: prospects for future therapies.

Authors:  Svenja Nölting; Ashley B Grossman
Journal:  Endocr Pathol       Date:  2012-03       Impact factor: 3.943

5.  Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma.

Authors:  Iñaki Comino-Méndez; Francisco J Gracia-Aznárez; Francesca Schiavi; Iñigo Landa; Luis J Leandro-García; Rocío Letón; Emiliano Honrado; Rocío Ramos-Medina; Daniela Caronia; Guillermo Pita; Alvaro Gómez-Graña; Aguirre A de Cubas; Lucía Inglada-Pérez; Agnieszka Maliszewska; Elisa Taschin; Sara Bobisse; Giuseppe Pica; Paola Loli; Rafael Hernández-Lavado; José A Díaz; Mercedes Gómez-Morales; Anna González-Neira; Giovanna Roncador; Cristina Rodríguez-Antona; Javier Benítez; Massimo Mannelli; Giuseppe Opocher; Mercedes Robledo; Alberto Cascón
Journal:  Nat Genet       Date:  2011-06-19       Impact factor: 38.330

6.  Functional interplay between c-Myc and Max in B lymphocyte differentiation.

Authors:  Mercedes Pérez-Olivares; Alfonsina Trento; Sara Rodriguez-Acebes; Daniel González-Acosta; David Fernández-Antorán; Sara Román-García; Dolores Martinez; Tania López-Briones; Carlos Torroja; Yolanda R Carrasco; Juan Méndez; Ignacio Moreno de Alborán
Journal:  EMBO Rep       Date:  2018-08-20       Impact factor: 8.807

7.  The nerve growth factor-responsive PC12 cell line does not express the Myc dimerization partner Max.

Authors:  R Hopewell; E B Ziff
Journal:  Mol Cell Biol       Date:  1995-07       Impact factor: 4.272

Review 8.  MYC Deregulation in Primary Human Cancers.

Authors:  Manpreet Kalkat; Jason De Melo; Katherine Ashley Hickman; Corey Lourenco; Cornelia Redel; Diana Resetca; Aaliya Tamachi; William B Tu; Linda Z Penn
Journal:  Genes (Basel)       Date:  2017-05-25       Impact factor: 4.096

9.  Somatic loss of function mutations in neurofibromin 1 and MYC associated factor X genes identified by exome-wide sequencing in a wild-type GIST case.

Authors:  Martin G Belinsky; Lori Rink; Kathy Q Cai; Stephen J Capuzzi; Yen Hoang; Jeremy Chien; Andrew K Godwin; Margaret von Mehren
Journal:  BMC Cancer       Date:  2015-11-10       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.